Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In December: Earnings Summary

CASI Pharmaceuticals

28/04/2023 14:31

* CASI Pharmaceuticals Inc  CASI.OQ  reported a quarterly
adjusted
loss of $1.44​​ per share for the quarter ended in December. The
mean expectation of two analysts for the quarter was for a loss
of 37 cents per share.
    * Revenue rose 66.6% to $15.26 million from a year ago;
analysts
expected $10.79 million. 
    * CASI Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.44​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * CASI Pharmaceuticals Inc shares had risen by 27.1% this
quarter and gained 64.7% so far this year.
    * The company reported a quarterly loss of $20.1 million.
    * Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is $10.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 28 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.37          -1.44          Missed
 Sep. 30 2022      -0.46          -0.38          Beat
 Jun. 30 2022      -0.64          -0.56          Beat
 Mar. 31 2022      -0.87          -0.60          Beat